科兴制药：向香港联交所递交H股发行上市申请

Core Viewpoint - The company has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025, indicating a strategic move to access international capital markets [1] Group 1 - The application materials submitted are in draft form and may be updated or revised as necessary [1] - The issuance, if implemented, will be limited to eligible foreign investors and qualified domestic investors who are authorized to conduct overseas securities investments according to Chinese laws and regulations [1]